4507:TYO
Shionogi & Co Ltd
2 744,50 JP¥
arrow_downward
-0,88%(-24,50) 1D
9-окт., 15:30:00 GMT+9 · JPY
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for 4507...
Open
2 758 JP¥
High
2 778 JP¥
Low
2 734 JP¥
Mkt. cap
2,44 трлн
Avg. vol.
2,93 млн
Volume
3,31 млн
Dividend
2,59%
Quarterly dividend
18 JP¥
Ex-dividend date
2026-ж., 29-сен.
P/E ratio
8,86
52-wk high
3 758 JP¥
52-wk low
2 392 JP¥
EPS
310 JP¥
Shares outstanding
314,50 млн
No. of employees
6 миң
Open
2 758 JP¥
High
2 778 JP¥
Low
2 734 JP¥
Mkt. cap
2,44 трлн
Avg. vol.
2,93 млн
Volume
3,31 млн
Dividend
2,59%
Quarterly dividend
18 JP¥
Ex-dividend date
2026-ж., 29-сен.
P/E ratio
8,86
52-wk high
3 758 JP¥
52-wk low
2 392 JP¥
EPS
310 JP¥
Shares outstanding
314,50 млн
No. of employees
6 миң
News stories
From web sources and news partners
Kalkine Media
·
38 мүнөт мурун
Are Streaming and Park Strength Driving Walt Disney's (NYSE:DIS) Rebound?
TradingView
·
45 мүнөт мурун
SPX: S&P 500 Nears Record as Traders Gear Up for Earnings, Inflation Data
Profile
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m.
On 5 October 2026, Shionogi announced an agreement to acquire IntraBio for US$2 billion through its US subsidiary, Shionogi Inc. Wikipedia
About Shionogi & Co Ltd
CEOIsao Teshirogi
Employees6,22 миң
Founded1878
Headquarters-
SectorPharmaceutical industry
Websiteshionogi.com